Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic has maintained an Overweight rating on Boston Scientific (NYSE:BSX) and raised the price target from $78 to $86.
August 22, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed its positive outlook on Boston Scientific by maintaining an Overweight rating and increasing the price target to $86, indicating confidence in the company's future performance.
The increase in the price target from $78 to $86 by Barclays suggests a positive outlook for Boston Scientific, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100